AGILON HEALTH INC

Insider Trading & Executive Data

AGL
NYSE
Healthcare
Medical Care Facilities

Start Free Trial

Get the full insider signal for AGL

41 insider trades in the last year. Go beyond summary counts with transaction-level detail, compensation intelligence, and institutional ownership context.

Trade-level insider transactions with filing links, transaction codes, and footnotes
Executive compensation trends by role with year-over-year comparisons
Institutional ownership shifts by quarter with top-holder concentration data
Form 144 and Form 8-K monitoring with AI analysis and CSV export tools

Insider Activity Summary

Insider Trades (1Y)
41
0 in last 30 days
Buy / Sell (1Y)
23/18
Acquisitions / Dispositions
Unique Insiders (1Y)
12
Active in past year
Insider Positions
20
Current holdings
Position Status
19/1
Active / Exited
Institutional Holders
186
Latest quarter
Board Members
33

Compensation & Governance

Avg Total Compensation
$3.5M
Latest year: 2024
Executives Covered
8
Comp records available
Form 8-K Events (1Y)
2
Personnel Changes (1Y)
2
Bonus Plan Events (1Y)
0
Organization Changes (1Y)
1
Board Appointments (1Y)
1
Board Departures (1Y)
1

Restricted Sales

Form 144 Filings (1Y)
0
Form 144 Insiders (1Y)
0
Planned Sale Shares (1Y)
0
Planned Sale Value (1Y)
$0.00
Price
$0.58
Market Cap
$244.3M
Volume
35,234.134
EPS
N/A
Revenue
$5.9B
Employees
1.1K
About AGILON HEALTH INC

Company Overview

Agilon Health is a value-based care operator that partners with community primary care physician groups through long-term professional service agreements and local risk-bearing entities (RBEs) to manage Medicare Advantage and Medicare FFS populations under global capitation and ACO arrangements. The company provides a technology and clinical platform (CORE, HCC Manager, Minerva), data/analytics, capital and operational support, and shares savings with physician partners; membership grew rapidly in 2024 (526,500 MA members) but has since softened into 2025 (~497,500). Revenue and membership trends are highly sensitive to CMS policy, MA bidding/benchmarks, risk-adjustment outcomes, payor contracting and required risk capital, and the business carries concentrated partner and regulatory risk.

Executive Compensation Practices

Given agilon’s model and the MD&A disclosures, executive pay is likely focused on growth and operating metrics that drive capitation economics: MA membership growth, PMPM medical margin (medical margin in absolute dollars and PMPM), risk-adjustment accuracy, quality/ACO shared-savings metrics, and adjusted EBITDA or cash runway. Long-term incentives (stock awards/RSUs and multi-year performance vesting) are appropriate because the company signs very long professional service agreements (typical 20-year terms) and needs to align executives with partner retention and multi-year margin improvement; the filings explicitly show stock‑based compensation is a material line item and was reduced in 2024. Compensation committees will also weigh liquidity and capital-raise risk (term/revolver maturities, letters of credit and capital commitments), so supplemental pay or retention awards tied to successful payor renewals, CMS performance thresholds (HEDIS/Star/ACO savings), and capital preservation milestones are plausible. Finally, intense regulatory oversight (CMS/OIG/DOJ, Stark/AKS, False Claims) and the sensitivity of revenue to actuarial and reserve judgments mean compensation plans often include clawbacks, compliance gating and discretionary adjustments for regulatory or settlement outcomes.

Insider Trading Considerations

Material nonpublic information at agilon is frequently tied to membership counts, payor contract renewals/terminations, CMS risk-adjustment data and MA bid/benchmark changes, timing of payor settlements and ACO/shared‑savings determinations, and liquidity/capital-raising plans — all events that can sharply move revenue and margins. Expect routine trading blackouts around monthly/quarterly enrollment and CMS bid windows, earnings releases, and known payor settlement periods; insider sales may also reflect personal liquidity needs driven by equity vesting rather than negative signal, given SBP was a notable expense reduction in 2024. Because the company may need additional capital and relies on letters of credit/credit facilities, watch insider activity before equity or debt raises as a potential signal of management views on valuation or financing necessity. Finally, compliance risk is elevated in this industry, so structured trading programs (10b5-1) and formal pre-clearance are likely used to avoid appearance of trading on sensitive health plan or CMS data.

Unlock Full Insider Trading Data
Get complete access to insider trades, executive compensation, institutional holdings, and AI-powered analysis for AGILON HEALTH INC and thousands of other companies.
Individual insider trade details with transaction history
Executive compensation breakdown by position
Institutional holder analysis with quarterly comparisons
Insider holdings with temporal change tracking
Form 144 restricted sale filings with details
Form 8-K governance events and personnel changes
10b5-1 trading plan analysis
AI-powered insights and conversational analysis
Board of directors profiles and governance data
Advanced filtering, sorting, and CSV export
No credit card required
Cancel anytime